Mitigating Infectious Risks of Anti-CD20 Therapies in MS

This lecture delves into anti-CD20 therapies for treating Multiple Sclerosis (MS), emphasizing their pharmacology, efficacy, and safety profiles. It explores how these therapies target B cells to manage MS progression, compares leading treatments like ocrelizumab and rituximab, and addresses risks such as infection and hypogammaglobulinemia. Strategies for risk mitigation, including immune monitoring and vaccination protocols, are discussed alongside emerging research on dosing regimens and...